Cefotetan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cefotetan
Cefotetan.svg
Systematic (IUPAC) name
(7S)-7-{[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)
1,3-dithietane-2-carbonyl]amino}-7-methoxy-
3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
AHFS/Drugs.com Consumer Drug Information
Pregnancy cat. B (US)
Legal status -only (US)
Routes Injection
Identifiers
CAS number 69712-56-7 YesY
ATC code J01DC05
PubChem CID 53025
DrugBank DB01330
ChemSpider 47904 YesY
UNII 48SPP0PA9Q YesY
KEGG D00260 N
ChEBI CHEBI:3499 N
ChEMBL CHEMBL474579 N
Chemical data
Formula C17H17N7O8S4 
Mol. mass 575.623 g/mol
 N (what is this?)  (verify)

Cefotetan is an injectable antibiotic of the cephamycin type for prophylaxis and treatment of bacterial infections. It is often grouped together with second-generation cephalosporins and has a similar antibacterial spectrum, but with additional anti-anaerobe coverage.

Cefotetan was developed by Yamanouchi. It is marketed outside Japan by AstraZeneca with the brand names Apatef and Cefotan.

Adverse effects[edit]

The chemical structure of cefotetan, like that of several other cephalosporins, contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase) and a reaction with ethanol similar to that produced by disulfiram (Antabuse), due to inhibition of aldehyde dehydrogenase.[1]

Spectrum of bacterial susceptibility[edit]

Cefotetan has a broad spectrum of activity and has been used to treat bacterial infections of the bone, skin, urinary tract, and lower respiratory tract. Notable species include Bacteroides, Streptococcus, and Escherichia. The following represents MIC susceptibility data for a few medically significant bacteria.

  • Escherichia coli: 0.06 µg/mL
  • Bacteroides fragilis: ≤0.06 µg/mL - 512 µg/mL
  • Clostridium perfringins: 1 µg/mL - 4 µg/mL

[2]


References[edit]

  1. ^ Stork CM (2006). "Antibiotics, antifungals, and antivirals". In Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA (eds.). Goldfrank's toxicologic emergencies. New York: McGraw-Hill. p. 847. ISBN 0-07-143763-0. Retrieved 2009-07-03. 
  2. ^ http://www.toku-e.com/Assets/MIC/Cefotetan.pdf

External links[edit]